Who Paid My Doc
Rebinyn
Biological Hemophilia
NDC 0169-7905-01
General payments
$469,338
Research payments
$2,492,830
Through program year 2025, $469,338 in general payments and $2,492,830 in research payments were reported against Rebinyn (Hemophilia).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
11 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $238 | 9 |
| 2024 | General | $29,467 | 81 |
| 2024 | Research | $244,645 | 13 |
| 2023 | General | $113,712 | 188 |
| 2023 | Research | $847,466 | 47 |
| 2022 | General | $224,365 | 283 |
| 2022 | Research | $494,409 | 136 |
| 2021 | General | $79,410 | 129 |
| 2021 | Research | $381,921 | 238 |
| 2020 | General | $22,146 | 89 |
| 2020 | Research | $524,388 | 262 |
Breakdown
The top 5 of 7 recipients; each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
779 general · 696 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.